|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
Open access 
|
4/2009
vol. 8 abstract:
Review paper
The hypoxic cell a target for selective cancer therapy
Bogdan Michalski
,
Anna Banyś
,
Agnieszka Drosdzol
,
Violetta Skrzypulec
,
Urszula Mazurek
Przegląd Menopauzalny 2009; 4: 196-201
Online publish date: 2009/09/07
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Hypoxia is an unfavourable factor which predisposes both to more aggressive disease course and frequent metastases as well as patients’ resistance to standard therapy procedures. The development of neoplasm is dependent on oxygen amount and nutritive products supplied by the new blood vessels’ network (angiogenesis) with following direct distant metastases formation by new lymphatic vessels (lymphangiogenesis). This statement constitutes a paradigm. Hypoxia is a pathophysiological factor for angiogenesis and lymphangiogenesis in the neoplastic tumor. According to the latest clinical research, it was confirmed that hypoxia is a fundamental problem in radiotherapy and low cell’s oxygen saturation accelerates neoplasm progression in spite of the cancer therapy used. Hypoxia might cause drug-resistance through the amplification of specific genes as well as the induction of stress-proteins related to hypoxia.
keywords:
hypoxia, angiogenesis, HIF – hypoxia inducible factor, apoptosis |
 |
